IRIS UniCatt

Criscuolo, Marianna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.734
EU - Europa 2.941
AS - Asia 2.496
SA - Sud America 545
AF - Africa 79
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 7
Totale 9.813
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.634
SG - Singapore 1.146
DE - Germania 1.095
CN - Cina 716
SE - Svezia 518
BR - Brasile 447
IT - Italia 282
UA - Ucraina 199
FR - Francia 168
PL - Polonia 140
IN - India 138
IE - Irlanda 127
GB - Regno Unito 109
VN - Vietnam 106
ID - Indonesia 91
FI - Finlandia 71
RU - Federazione Russa 68
CA - Canada 47
TR - Turchia 43
AR - Argentina 34
BD - Bangladesh 33
MX - Messico 33
HK - Hong Kong 31
NL - Olanda 31
ES - Italia 26
JP - Giappone 26
IQ - Iraq 25
ZA - Sudafrica 24
NO - Norvegia 19
PK - Pakistan 19
BE - Belgio 18
KR - Corea 18
AT - Austria 16
SA - Arabia Saudita 14
CO - Colombia 13
CI - Costa d'Avorio 12
AU - Australia 11
CL - Cile 11
EC - Ecuador 11
JO - Giordania 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
LT - Lituania 9
CZ - Repubblica Ceca 8
EG - Egitto 8
IR - Iran 8
MA - Marocco 8
UZ - Uzbekistan 8
KE - Kenya 7
NP - Nepal 7
PY - Paraguay 7
TH - Thailandia 7
DZ - Algeria 6
GR - Grecia 6
IL - Israele 6
PE - Perù 6
AZ - Azerbaigian 5
BO - Bolivia 5
CH - Svizzera 5
PH - Filippine 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
JM - Giamaica 4
KZ - Kazakistan 4
PS - Palestinian Territory 4
RO - Romania 4
BB - Barbados 3
BG - Bulgaria 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
LV - Lettonia 3
MD - Moldavia 3
MY - Malesia 3
TN - Tunisia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BW - Botswana 2
EU - Europa 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CR - Costa Rica 1
DK - Danimarca 1
GH - Ghana 1
IS - Islanda 1
KH - Cambogia 1
LK - Sri Lanka 1
MM - Myanmar 1
OM - Oman 1
PT - Portogallo 1
Totale 9.806
Salva come PNG Salva come JPEG
Città #
Singapore 562
Chandler 559
Ashburn 291
Frankfurt am Main 148
Jacksonville 141
Los Angeles 128
Warsaw 126
Chicago 121
Dublin 121
Beijing 120
San Mateo 113
New York 110
Ann Arbor 109
Houston 97
Dearborn 96
Woodbridge 95
Nanjing 94
Munich 90
Jakarta 83
Wilmington 83
Hefei 69
Fairfield 57
Milan 57
Boston 55
Buffalo 54
São Paulo 52
Bremen 44
Hyderabad 44
Moscow 44
Dallas 42
Cattolica 41
Nürnberg 40
Seattle 39
Nanchang 37
Redwood City 37
Lawrence 34
Princeton 34
Ho Chi Minh City 33
Rome 31
Hanoi 30
Hong Kong 30
Salt Lake City 26
The Dalles 26
Hangzhou 23
London 23
Marseille 23
Santa Clara 23
Shanghai 23
Orem 22
Montreal 21
Leawood 20
Shenyang 20
Mountain View 19
Brussels 18
Cambridge 18
Izmir 17
Kunming 17
Redmond 17
Seoul 17
Brooklyn 16
Chatsworth 16
Tianjin 16
Augusta 15
Kent 15
Poplar 15
Tokyo 15
Auburn Hills 14
Falls Church 13
Nuremberg 13
Pune 13
Tampa 13
Zhengzhou 13
Abidjan 12
Belo Horizonte 12
Chennai 12
Denver 12
Guangzhou 12
Hebei 12
Lappeenranta 12
Boardman 11
Changsha 11
Elk Grove Village 11
Johannesburg 11
Norwalk 11
Phoenix 11
Amman 10
Atlanta 10
Dhaka 10
Jiaxing 10
Philadelphia 10
Washington 10
Helsinki 9
Jinan 9
Rio de Janeiro 9
Toronto 9
Turku 9
University Park 9
Baghdad 8
Cape Town 8
Jeddah 8
Totale 5.039
Salva come PNG Salva come JPEG
Nome #
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 405
Fanconi anemia gene variants in therapy-related myeloid neoplasms 302
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 215
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 211
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 184
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 183
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 173
Why methylation is not a marker predictive of response to hypomethylating agents 172
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 170
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 170
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 167
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 165
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 163
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 163
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 161
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 160
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 159
Epigenetic changes in therapy-related MDS/AML 156
Similarities and differences between therapy-related and elderly acute myeloid leukemia 152
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 148
Primary plasma cell leukemia followed by testicular plasmacytoma 145
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 145
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 143
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 141
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 141
Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report 139
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 133
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 131
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 129
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 125
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 125
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 124
Outcome of therapy-related myeloid neoplasms treated with azacitidine 120
Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey 119
Clonal evolution in therapy-related neoplasms 116
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 116
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 115
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 113
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 112
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS 111
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 110
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 109
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 104
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 104
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 103
Therapy-related myeloid neoplasms: Clinical perspectives 99
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. 95
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 94
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 93
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 92
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 91
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 90
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 90
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 90
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper 90
Systemic mastocytosis revisited with an emphasis on skeletal manifestations 89
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 86
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 84
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 83
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 83
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 82
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 81
A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group 80
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry 79
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 78
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 77
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope 76
The validity of the fifth and the 10th Body Mass Index percentile as weight cut-offs for anorexia nervosa in adolescence: No evidence from quantitative and network investigation of psychopathology 76
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 75
Fungaemia in haematological malignancies: SEIFEM-2015 survey 74
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study 72
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 71
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 71
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report 69
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 68
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 68
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation 66
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 64
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome 62
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 60
Mastocytosis: One Word for Different Diseases 58
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 52
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients 51
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 46
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 44
Totale 9.901
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021436 0 0 0 0 0 82 84 18 57 53 124 18
2021/2022693 64 40 8 29 51 35 13 122 37 72 96 126
2022/20231.452 188 207 123 267 77 181 50 110 157 20 52 20
2023/2024736 37 186 27 27 29 131 60 15 11 26 90 97
2024/20251.856 49 58 129 54 155 24 90 73 228 171 563 262
2025/20262.375 605 92 223 412 680 363 0 0 0 0 0 0
Totale 9.901